<DOC>
	<DOCNO>NCT01531790</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , clinical efficacy pharmacokinetics continuous Endostar intravenous infusion combine pemetrexed carboplatin advance non small cell lung cancer ( NSCLC ) patient .</brief_summary>
	<brief_title>A Study Continuous Endostar Intravenous Infusion Combined With Pemetrexed Carboplatin Advanced Non Small Cell Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histological cytological diagnosis inoperable stage IIIB/IV nonsquamous NSCLC At least one measurable lesion ( RECIST criterion ) Life expectancy &gt; 3 month ECOG performance status 02 Adequate hematologic function : WBC ≥ 3.0×109 /L，ANC ≥ 1.5×109 /L，Hb ≥ 90 g/L，PLT ≥ 100×109 /L Adequate renal , hepatic coagulation function Written inform consent With uncontrollable malignant pleural effusion ascites Thoracic abdominal surgery within 28 day prior study entry History cerebral stroke TIA within 6 month prior study entry With uncontrollable hypertension , hypertensive emergency hypertensive encephalopathy Arrhythmia need antiarrhythmic treatment , history angina pectoris , myocardial infarction , myocardial ischemia congestive heart failure ( &gt; NYHA class II ) With serious infection ( &gt; NCI CTC grade 2 ) Gastrointestinal perforation , fistula formation , and/or intra‑abdominal abscess within 6 month prior study entry Symptomatic brain metastasis Patient epilepsy History HIV infection chronic hepatitis B C Allergic study drug Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Endostar</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Phase I</keyword>
</DOC>